Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis

Mélanie Drolet, Élodie Bénard, Norma Pérez, Marc Brisson, HPV Vaccination Impact Study Group, Hammad Ali, Marie-Claude Boily, Vincenzo Baldo, Paul Brassard, Julia M L Brotherton, Denton Callander, Marta Checchi, Eric P F Chow, Silvia Cocchio, Tina Dalianis, Shelley L Deeks, Christian Dehlendorff, Basil Donovan, Christopher K Fairley, Elaine W Flagg, Julia W Gargano, Suzanne M Garland, Nathalie Grün, Bo T Hansen, Christopher Harrison, Eva Herweijer, Teresa M Imburgia, Anne M Johnson, Jessica A Kahn, Kimberley Kavanagh, Susanne K Kjaer, Erich V Kliewer, Bette Liu, Dorothy A Machalek, Lauri Markowitz, David Mesher, Christian Munk, Linda Niccolai, Mari Nygård, Gina Ogilvie, Jeannie Oliphant, Kevin G Pollock, Maria Jesús Purriños-Hermida, Megan A Smith, Marc Steben, Anna Söderlund-Strand, Pam Sonnenberg, Pär Sparen, Clare Tanton, Cosette M Wheeler, Petra J Woestenberg, Bo Nancy Yu, Mélanie Drolet, Élodie Bénard, Norma Pérez, Marc Brisson, HPV Vaccination Impact Study Group, Hammad Ali, Marie-Claude Boily, Vincenzo Baldo, Paul Brassard, Julia M L Brotherton, Denton Callander, Marta Checchi, Eric P F Chow, Silvia Cocchio, Tina Dalianis, Shelley L Deeks, Christian Dehlendorff, Basil Donovan, Christopher K Fairley, Elaine W Flagg, Julia W Gargano, Suzanne M Garland, Nathalie Grün, Bo T Hansen, Christopher Harrison, Eva Herweijer, Teresa M Imburgia, Anne M Johnson, Jessica A Kahn, Kimberley Kavanagh, Susanne K Kjaer, Erich V Kliewer, Bette Liu, Dorothy A Machalek, Lauri Markowitz, David Mesher, Christian Munk, Linda Niccolai, Mari Nygård, Gina Ogilvie, Jeannie Oliphant, Kevin G Pollock, Maria Jesús Purriños-Hermida, Megan A Smith, Marc Steben, Anna Söderlund-Strand, Pam Sonnenberg, Pär Sparen, Clare Tanton, Cosette M Wheeler, Petra J Woestenberg, Bo Nancy Yu

Abstract

Background: More than 10 years have elapsed since human papillomavirus (HPV) vaccination was implemented. We did a systematic review and meta-analysis of the population-level impact of vaccinating girls and women against human papillomavirus on HPV infections, anogenital wart diagnoses, and cervical intraepithelial neoplasia grade 2+ (CIN2+) to summarise the most recent evidence about the effectiveness of HPV vaccines in real-world settings and to quantify the impact of multiple age-cohort vaccination.

Methods: In this updated systematic review and meta-analysis, we used the same search strategy as in our previous paper. We searched MEDLINE and Embase for studies published between Feb 1, 2014, and Oct 11, 2018. Studies were eligible if they compared the frequency (prevalence or incidence) of at least one HPV-related endpoint (genital HPV infections, anogenital wart diagnoses, or histologically confirmed CIN2+) between pre-vaccination and post-vaccination periods among the general population and if they used the same population sources and recruitment methods before and after vaccination. Our primary assessment was the relative risk (RR) comparing the frequency (prevalence or incidence) of HPV-related endpoints between the pre-vaccination and post-vaccination periods. We stratified all analyses by sex, age, and years since introduction of HPV vaccination. We used random-effects models to estimate pooled relative risks.

Findings: We identified 1702 potentially eligible articles for this systematic review and meta-analysis, and included 65 articles in 14 high-income countries: 23 for HPV infection, 29 for anogenital warts, and 13 for CIN2+. After 5-8 years of vaccination, the prevalence of HPV 16 and 18 decreased significantly by 83% (RR 0·17, 95% CI 0·11-0·25) among girls aged 13-19 years, and decreased significantly by 66% (RR 0·34, 95% CI 0·23-0·49) among women aged 20-24 years. The prevalence of HPV 31, 33, and 45 decreased significantly by 54% (RR 0·46, 95% CI 0·33-0·66) among girls aged 13-19 years. Anogenital wart diagnoses decreased significantly by 67% (RR 0·33, 95% CI 0·24-0·46) among girls aged 15-19 years, decreased significantly by 54% (RR 0·46, 95% CI 0.36-0.60) among women aged 20-24 years, and decreased significantly by 31% (RR 0·69, 95% CI 0·53-0·89) among women aged 25-29 years. Among boys aged 15-19 years anogenital wart diagnoses decreased significantly by 48% (RR 0·52, 95% CI 0·37-0·75) and among men aged 20-24 years they decreased significantly by 32% (RR 0·68, 95% CI 0·47-0·98). After 5-9 years of vaccination, CIN2+ decreased significantly by 51% (RR 0·49, 95% CI 0·42-0·58) among screened girls aged 15-19 years and decreased significantly by 31% (RR 0·69, 95% CI 0·57-0·84) among women aged 20-24 years.

Interpretation: This updated systematic review and meta-analysis includes data from 60 million individuals and up to 8 years of post-vaccination follow-up. Our results show compelling evidence of the substantial impact of HPV vaccination programmes on HPV infections and CIN2+ among girls and women, and on anogenital warts diagnoses among girls, women, boys, and men. Additionally, programmes with multi-cohort vaccination and high vaccination coverage had a greater direct impact and herd effects.

Funding: WHO, Canadian Institutes of Health Research, Fonds de recherche du Québec - Santé.

Conflict of interest statement

Declaration of interests

The authors listed in this paper declare no competing interests. Please see the appendix for the declaration of interests of the authors listed as study group members.

Copyright © 2019 Elsevier Ltd. All rights reserved.

Figures

Figure 1:. Study selection
Figure 1:. Study selection
Two articles on anogenital warts from our previous systematic review and meta-analysis were not included in this update: Sandø and colleagues and Nsouli-Maktabi and colleagues. Sandø and colleagues was one of two studies we had previously found that analysed the entire Danish population for the same period, but we included the study by Baandrup and colleagues in our current analysis because they updated their data and had a longer follow-up. We excluded the study by Nsouli-Maktabi and colleagues because it was done among members of the US armed forces and not in the general population. NHANES=National Health and Nutrition Examination Survey.
Figure 2:. Changes in the prevalence of…
Figure 2:. Changes in the prevalence of HPV infections between pre-vaccination and post-vaccination periods
HPV=human papillomavirus. *p values are associated with the χ2 statistic.
Figure 3:. Changes in anogenital wart diagnoses…
Figure 3:. Changes in anogenital wart diagnoses between pre-vaccination and post-vaccination periods in countries using the quadrivalent vaccine
*p values are associated with the χ2 statistic.
Figure 4:. Changes in anogenital wart diagnoses…
Figure 4:. Changes in anogenital wart diagnoses during the 8 years after the introduction of girls-only human papillomavirus vaccination in countries using the quadrivalent vaccine
We stratified by number of cohorts vaccinated and routine vaccination coverage. Countries with single-cohort vaccination and/or low coverage (in red) were Canada (Ontario, Manitoba,) and Italy with single-cohort vaccination and high coverage; and Germany,, Belgium, Sweden,, and the USA,, with multi-cohort vaccination and low coverage. Countries with multi-cohort vaccination and high coverage (in blue) were Australia,,,,, Denmark,, New Zealand,, and Canada (Quebec).
Figure 5:. Changes in CIN2+ among screened…
Figure 5:. Changes in CIN2+ among screened girls and women between the pre-vaccination and post-vaccination periods
CIN2+=cervical intraepithelial neoplasia grade 2+. *p values are associated with the χ2 statistic.
Figure 6:. Changes in CIN2+ among screened…
Figure 6:. Changes in CIN2+ among screened girls and women during the first 7 years after the introduction of girls-only human papillomavirus vaccination, in countries with multi-cohort vaccination and high vaccination coverage
Countries with multi-cohort vaccination and high coverage (≥50%) were Australia,, Canada (British Columbia), Denmark, Scotland, and the USA.,,, For CIN2+ analysis, the USA was categorised as a country with multi-cohort vaccination and high routine vaccination coverage because several US data indicate an association between screening participation and human papillomavirus vaccination.,,, Thus, the vaccination coverage among screened girls and women is likely to be higher than the overall vaccination coverage in the population. We did a sensitivity analysis excluding the USA from countries with multi-cohort and high vaccination coverage and results were unchanged. CIN2+=cervical intraepithelial neoplasia grade 2+.

References

    1. Bruni L, Diaz M, Barrionuevo-Roses L, et al. Worldwide female and male HPV vaccination coverage from 2006 to 2016. International Papillomavirus Conference; Cape Town; Feb 28–March 4, 2017.
    1. Cervical Cancer Action. Global progress in HPV vaccination. (accessed May 23, 2018).
    1. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15: 565–80.
    1. Franco E, Schiffman M, Wacholder S, Stanley M. Methodological issues for trials of vaccine efficacy against HPV types 16 and 18 In: ARC HPV Working Group. Primary end-points for prophylactic vaccine trials. Lyon: International Agency for Research on Cancer, 2014: 39–45.
    1. WHO. Human papillomavirus vaccines: WHO position paper, May 2017–recommendations. Vaccine 2017; 35: 5753–55.
    1. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
    1. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009; 199: 805–14.
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–88.
    1. Deeks JJ, Higgins JPT, on behalf of the Statistical Methods Group of the Cochrane Collaboration. Statistical algorithms in Review Manager 5 (accessed May 23, 2014).
    1. Deeks JJ, Higgins PT, Altman DG. Analysing data and undertaking meta-analyses In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
    1. Dillner J, Nygård M, Munk C, et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine 2018; 36: 3820–29.
    1. Chow EP, Danielewski JA, Fehler G, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 2015; 15: 1314–23.
    1. Chow EPF, Machalek DA, Tabrizi SN, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infect Dis 2017; 17: 68–77.
    1. Cummings T, Zimet GD, Brown D, et al. Reduction of HPV infections through vaccination among at-risk urban adolescents. Vaccine 2012; 30: 5496–99.
    1. Dunne EF, Naleway A, Smith N, et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012–2013. J Infect Dis 2015; 212: 1970–75.
    1. Grün N, Ährlund-Richter A, Franzén J, et al. Follow-up on oral and cervical human papillomavirus prevalence 2013–2015 in youth at a youth clinic in Stockholm, Sweden. Infect Dis (Lond) 2016; 48: 169–70.
    1. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110: 2804–11.
    1. Cameron RL, Kavanagh K, Pan J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis 2016; 22: 56–64.
    1. Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis 2017; 17: 1293–302.
    1. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012; 130: e249–56.
    1. Kahn JA, Widdice LE, Ding L, et al. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis 2016; 63: 1281–87.
    1. Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination. J Infect Dis 2018; 217: 1590–600.
    1. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis 2013; 208: 385–93.
    1. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics 2016; 137: e20151968.
    1. Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction— National Health and Nutrition Examination Survey, United States, 2003–2014. J Infect Dis 2017; 216: 594–603.
    1. Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open 2016; 6: e009915.
    1. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32: 26–32.
    1. Mesher D, Panwar K, Thomas SL, et al. The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010–2016. J Infect Dis 2018; 218: 911–21.
    1. Purriños-Hermida MJ, Santiago-Pérez MI, Treviño M, et al. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. PLoS One 2018; 13: e0201653.
    1. Söderlund-Strand A, Uhnoo I, Dillner J. Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev 2014; 23: 2757–64.
    1. Sonnenberg P, Clifton S, Beddows S, et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382: 1795–806.
    1. Tabrizi SN, Brotherton JML, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206: 1645–51.
    1. Tabrizi SN, Brotherton JML, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14: 958–66.
    1. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013; 346: f2032.
    1. Ali H, McManus H, O’Connor CC, et al. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Med J Aust 2017; 206: 204–09.
    1. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2015; 91: 214–19.
    1. Callander D, Ali H, Donovan B. Genital Warts Surveillance Network report 2004–2015. Sydney, NSW: The Kirby Institute, 2016.
    1. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40: 130–35.
    1. Bollerup S, Baldur-Felskov B, Blomberg M, Baandrup L, Dehlendorff C, Kjaer SK. Significant reduction in the incidence of genital warts in young men 5 years into the Danish human papillomavirus vaccination program for girls and women. Sex Transm Dis 2016; 43: 238–42.
    1. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health 2012; 102: 833–35.
    1. Cocchio S, Baldovin T, Bertoncello C, et al. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis 2017; 17: 249.
    1. Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One 2015; 10: e0132404.
    1. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103: 1428–35.
    1. Flagg EW, Torrone EA. Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health 2018; 108: 112–19.
    1. Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL. Early impact of Ontario’s human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): a population-based assessment. Vaccine 2016; 34: 4678–83.
    1. Harrison C, Britt H, Garland S, et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One 2014; 9: e105967.
    1. Howell-Jones R, Soldan K, Wetten S, et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis 2013; 208: 1397–403.
    1. Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect 2017; 93: 125–28.
    1. Kliewer EV, Mahmud SM, Demers AA, Lambert P, Musto G. Quadrivalent HPV vaccination and the incidence of anogenital warts in Manitoba, Canada. 28th International Papillomavirus Conference; San Juan, Puerto Rico; Nov 30–Dec 6, 2012 Abstract E07–663.
    1. Thompson LH, Nugent Z, Blanchard JF, Ens C, Yu BN. Increasing incidence of anogenital warts with an urban-rural divide among males in Manitoba, Canada, 1990–2011. BMC Public Health 2016; 16: 219.
    1. Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206: 860–66.
    1. Herweijer E, Ploner A, Sparén P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine 2018; 36: 1917–20.
    1. Liu B, Donovan B, Brotherton JM, Saville M, Kaldor JM. Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011. Sex Transm Infect 2014; 90: 532–37.
    1. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany—an ecologic study. Sex Transm Dis 2013; 40: 28–31.
    1. Thöne K, Horn J, Mikolajczyk R. Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC Infect Dis 2017; 17: 564.
    1. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J 2011; 124: 51–58.
    1. Oliphant J, Stewart J, Saxton P, Lo M, Perkins N, Ward D. Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. N Z Med J 2017; 130: 9–16.
    1. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis 2015; 211: 91–99.
    1. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis 2016; 16: 52.
    1. Sonnenberg P, Tanton C, King E, et al. Genital warts & HPV 6/11 in the British population: data from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). 31st International Papillomavirus Conference; Cape Town; Feb 28–March 4, 2017 Abstract 454.
    1. Steben M, Ouhoummane N, Rodier C, Sinyavskaya L, Brassard P. The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada. J Med Virol 2018; 90: 592–98.
    1. Woestenberg PJ, King AJ, van der Sande MA, et al. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors. J Infect 2017; 74: 393–400.
    1. Sandø N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women – an ecological study. Acta Derm Venereol 2014; 94: 288–92.
    1. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, Gaydos JC. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR 2013; 20: 17–20.
    1. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014; 25: 915–22.
    1. Baldur-Felskov B, Munk C, Nielsen TSS, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012. Cancer Causes Control 2015; 26: 1105–16.
    1. Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol 2017; 3: 833–37.
    1. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085–92.
    1. Australian Institute of Health and Welfare. Cervical screening in Australia 2013–2014. National Cervical Screening Program. (accessed Nov 2, 2018).
    1. Australian Institute of Health and Welfare. Cervical screening in Australia: 2018. National Cervical Screening Program. (accessed Jan 25, 2019).
    1. Flagg EW, Torrone EA, Weinstock H. Ecological Association of Human Papillomavirus Vaccination with Cervical Dysplasia Prevalence in the United States, 2007–2014. Am J Public Health 2016; 106: 2211–18.
    1. Gargano JW, Park IU, Griffin MR, et al. Trends in high-grade cervical lesions and cervical cancer screening in five states, 2008–2015. Clin Infect Dis 2018; 10.1093/cid/ciy707.
    1. Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE. Declining rates of high-grade cervical lesions in young women in Connecticut, 2008–2011. Cancer Epidemiol Biomarkers Prev 2013; 22: 1446–50.
    1. Niccolai LM, Meek JI, Brackney M, Hadler JL, Sosa LE, Weinberger DM. Declines in human papillomavirus (HPV)–associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, United States, 2008–2015. Clin Infect Dis 2017; 65: 884–89.
    1. Liaw KL, Kjaer S, Nygard M, Dillner J. Utilization of nordic countries national registries to monitor the impact of HPV vaccination. Pharmacoepidemiol Drug Saf 2014; 23: 356.
    1. Ogilvie GS, Naus M, Money DM, et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer 2015; 137: 1931–37.
    1. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111: 1824–30.
    1. Chen HY, Kessler CL, Mori N, Chauhan SP. Cervical cancer screening in the United States, 1993–2010: characteristics of women who are never screened. J Womens Health (Larchmt) 2012; 21: 1132–38.
    1. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105: 175–201.
    1. Tiro JA, Tsui J, Bauer HM, Yamada E, Kobrin S, Breen N. Human papillomavirus vaccine use among adolescent girls and young adult women: an analysis of the 2007 California Health Interview Survey. J Womens Health (Larchmt) 2012; 21: 656–65.
    1. Chao C, Silverberg MJ, Becerra TA, et al. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system. Am J Obstet Gynecol 2017; 216: 151.e1–9.
    1. Drolet M, Laprise JF, Brotherton JML, et al. The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation. J Infect Dis 2017; 216: 1205–09.
    1. Chaiyakunapruk N, Ng SS. Summary of evidence. Human papillomavirus (HPV) vaccination: an updated systematic review of cost-effectiveness analyses. Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE); Geneva; October, 2016.
    1. WHO. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89: 465–91.
    1. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination —updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2016; 65: 1405–08.
    1. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23: 569–78.
    1. National Advisory Committee on Immunization (NACI). Statement on human papillomavirus vaccine. An advisory committee statement (ACS). Can Commun Dis Rep 2007; 33 (ACS-2): 1–31.
    1. US Food and Drug Administration. Vaccines, blood & biologics: Gardasil. (accessed May 2, 2019).
    1. European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries. Stockholm: January, 2008. (accessed May 2, 2019).
    1. Richardson LA, Tota J, Franco EL. Optimizing technology for cervical cancer screening in high-resource settings. Expert Rev Obstet Gynecol 2011; 6: 343–53.
    1. Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the compass pilot randomised trial. PLoS Med 2017; 14: e1002388.
    1. Drolet M, Boily MC, Greenaway C, et al. Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination. Cancer Epidemiol Biomarkers Prev 2013; 22: 641–52.
    1. Herweijer E, Feldman AL, Ploner A, et al. The participation of HPV-vaccinated women in a national cervical screening program: population-based cohort study. PLoS One 2015; 10: e0134185.
    1. Tanton C, Soldan K, Beddows S, et al. High-risk human papillomavirus (HPV) infection and cervical cancer prevention in Britain: Evidence of differential uptake of interventions from a probability survey. Cancer Epidemiol Biomarkers Prev 2015; 24: 842–53.
    1. Brotherton JML, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust 2016; 204: 184.
    1. Liu G, Hariri S, Bradley H, Gottlieb SL, Leichliter JS, Markowitz LE. Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States. Sex Transm Dis 2015; 42: 20–26.
    1. Lewis R, Tanton C, Mercer CH, et al. Heterosexual practices among young people in Britain: evidence from three national surveys of sexual attitudes and lifestyles. J Adolesc Health 2017; 61: 694–702.
    1. Mercer CH, Tanton C, Prah P, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382: 1781–94.
    1. Rissel C, Badcock PB, Smith AM, et al. Heterosexual experience and recent heterosexual encounters among Australian adults: the Second Australian Study of Health and Relationships. Sex Health 2014; 11: 416–26.
    1. Jensen KE, Munk C, Sparen P, et al. Women’s sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand 2011; 90: 459–67.
    1. Stenhammar C, Ehrsson YT, Åkerud H, Larsson M, Tydén T. Sexual and contraceptive behavior among female university students in Sweden—repeated surveys over a 25-year period. Acta Obstet Gynecol Scand 2015; 94: 253–59.
    1. Herlitz CA, Forsberg M. Sexual behaviour and risk assessment in different age cohorts in the general population of Sweden (1989–2007). Scand J Public Health 2010; 38: 32–39.
    1. Cocchio S, Bertoncello C, Baldovin T, Buja A, Majori S, Baldo V. Self-reported genital warts among sexually-active university students: a cross-sectional study. BMC Infect Dis 2018; 18: 41.
    1. Marino C, Vieno A, Lenzi M, Santinello M. Time trends in adolescent sexual behaviour in Italy. Sex Health 2014; 11: 379–80.
    1. Mori S, Nakao S, Kukimoto I, Kusumoto-Matsuo R, Kondo K, Kanda T. Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci 2011; 102: 1223–27.
    1. Tota JE, Ramanakumar AV, Jiang M, et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am J Epidemiol 2013; 178: 625–34.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera